









시장가
/
주식
/
nasdaq-txg
/

10X Genomics Inc

TXG

18.340USD

+1.880+11.42%

종가 11/21, 16:00（ET）시세는 15분 지연됩니다

2.32B시가총액

손실P/E TTM



10X Genomics Inc

18.340

+1.880+11.42%

개요 회사 금융 분석

개요

회사

금융

분석

자세한 내용은 10X Genomics Inc 회사

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

10X Genomics Inc 정보



종목 코드 TXG

회사 이름10X Genomics Inc

상장일Sep 12, 2019

CEOMr. Serge Wilson Saxonov, Ph.D.

직원 수1306

유형Ordinary Share

회계 연도 종료Sep 12

주소6230 Stoneridge Mall Road

도시PLEASANTON

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호94588

전화19254017300

웹사이트https://www.10xgenomics.com/

종목 코드 TXG

상장일Sep 12, 2019

CEOMr. Serge Wilson Saxonov, Ph.D.

10X Genomics Inc의 회사 임원진



이름

이름/직위

직위

주식 보유

변동

Mr. Serge Wilson Saxonov, Ph.D.

Chief Executive Officer, Co-Founder, Director

1.06M

-0.09%

Dr. John R. Stuelpnagel

Independent Chairman of the Board

369.61K

+4.34%

Whitaker (Eric S)

Chief Legal Officer

202.20K

+29.09%

Mr. Sridhar (Sri) Kosaraju

Independent Director

59.45K

+34.83%

Dr. Benjamin J. Hindson, Ph.D.

President, Co-Founder, Chief Scientific Officer, Director

44.69K

-14.35%

Ms. Kimberly J. (Kim) Popovits

Independent Director

28.62K

+115.82%

Dr. Shehnaaz Suliman, M.D.

Independent Director

28.62K

+115.82%

Mr. Adam S. Taich

Chief Financial Officer

Mr. Alan V. Mateo

Independent Director

Dr. Sarah A. Teichmann

Independent Director

이름

이름/직위

직위

주식 보유

변동

Mr. Serge Wilson Saxonov, Ph.D.

Chief Executive Officer, Co-Founder, Director

1.06M

-0.09%

Dr. John R. Stuelpnagel

Independent Chairman of the Board

369.61K

+4.34%

Whitaker (Eric S)

Chief Legal Officer

202.20K

+29.09%

Mr. Sridhar (Sri) Kosaraju

Independent Director

59.45K

+34.83%

Dr. Benjamin J. Hindson, Ph.D.

President, Co-Founder, Chief Scientific Officer, Director

44.69K

-14.35%

Ms. Kimberly J. (Kim) Popovits

Independent Director

28.62K

+115.82%

수익 분석

통화: USD마지막 업데이트: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Consumables

122.19M

70.66%

Products and services revenue

27.75M

16.05%

Instruments

14.50M

8.38%

Services

8.47M

4.90%

지역별USD

이름

수익

비율

United States

103.49M

59.85%

Europe, the Middle East and Africa

34.73M

20.09%

China

23.17M

13.40%

Asia Pacific

8.85M

5.12%

Americas

2.67M

1.54%

사업별

지역별

사업별USD

이름

수익

비율

Consumables

122.19M

70.66%

Products and services revenue

27.75M

16.05%

Instruments

14.50M

8.38%

Services

8.47M

4.90%

주식 보유 통계

마지막 업데이트: Wed, Nov 19

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

11.38%

ARK Investment Management LLC

10.21%

BlackRock Institutional Trust Company, N.A.

6.68%

Fidelity Management & Research Company LLC

6.19%

Millennium Management LLC

4.67%

기타

60.88%

주주

비율

The Vanguard Group, Inc.

11.38%

ARK Investment Management LLC

10.21%

BlackRock Institutional Trust Company, N.A.

6.68%

Fidelity Management & Research Company LLC

6.19%

Millennium Management LLC

4.67%

기타

60.88%

주주 유형

주주

비율

Investment Advisor

52.15%

Investment Advisor/Hedge Fund

27.16%

Hedge Fund

14.44%

Research Firm

6.24%

Bank and Trust

5.01%

Venture Capital

1.88%

Individual Investor

1.82%

Family Office

0.84%

Pension Fund

0.54%

기관 주식 보유



마지막 업데이트: Wed, Oct 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q3

675

117.21M

102.45%

-24.61M

2025Q2

669

120.42M

108.39%

-15.20M

2025Q1

687

115.67M

104.27%

-8.84M

2024Q4

689

107.08M

98.92%

-12.41M

2024Q3

682

106.90M

100.39%

-9.08M

2024Q2

691

105.36M

99.70%

-5.09M

2024Q1

762

106.36M

101.17%

-3.12M

2023Q4

817

100.80M

96.01%

-9.73M

2023Q3

835

96.86M

93.80%

-12.55M

2023Q2

857

94.98M

96.77%

-15.37M

주주 활동



이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

12.42M

10.85%

+1.32M

+11.92%

Jun 30, 2025

ARK Investment Management LLC

13.89M

12.14%

+1.05M

+8.15%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

7.58M

6.63%

+2.17M

+40.18%

Jun 30, 2025

Fidelity Management & Research Company LLC

7.64M

6.68%

-930.78K

-10.85%

Jun 30, 2025

Millennium Management LLC

2.88M

2.52%

-2.65M

-47.89%

Jun 30, 2025

Sumitomo Mitsui Trust Bank, Limited

6.02M

5.26%

+654.60K

+12.20%

Jun 30, 2025

Wellington Management Company, LLP

1.89M

1.65%

+1.89M

Jun 30, 2025

Quantinno Capital Management LP

2.23M

1.95%

+1.51M

+207.23%

Jun 30, 2025

BofA Global Research (US)

2.91M

2.54%

+350.99K

+13.74%

Jun 30, 2025

주식 배당금



지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

데이터 없음

주식 분할



날짜

유형

비율

데이터 없음

날짜

유형

비율

데이터 없음

자주 묻는 질문

10X Genomics Inc의 상위 5대 주주는 누구인가요?



10X Genomics Inc의 상위 5대 주주는 다음과 같습니다:
The Vanguard Group, Inc.는 12.42M주의 주식을 보유하고 있으며, 전체 주식의 10.85%를 차지합니다.
ARK Investment Management LLC는 13.89M주의 주식을 보유하고 있으며, 전체 주식의 12.14%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 7.58M주의 주식을 보유하고 있으며, 전체 주식의 6.63%를 차지합니다.
Fidelity Management & Research Company LLC는 7.64M주의 주식을 보유하고 있으며, 전체 주식의 6.68%를 차지합니다.
Millennium Management LLC는 2.88M주의 주식을 보유하고 있으며, 전체 주식의 2.52%를 차지합니다.